University of Valencia logoLogo CSIC Logo del portal

BlockAce

This collaboration will employ a multi-disciplinary approach to identify inhibitors of SARS-CoV-2 receptor binding and entry. Combining expertise in medicinal chemistry, computational chemical biology, structural biology, and virology, 3 parallel approaches will be employed: (1) Immediate testing of compound libraries (>1,400) using a high-throughput cell assay for SARS-CoV-2 receptor binding and entry. (2) Computational screening and design, synthesis, and evaluation (3). Development of protein-based inhibitors derived from the ACE2 receptor. The final evaluation of hits for effectiveness and drug resistance will be done with SARS-CoV-2.
Acronym

BlockAce

Description

Title: Multidisciplinary approach to blocking SARS-CoV-2 entry through antivirals and Decoy-ACE2 fragments

Research group: Viral Biology

This collaboration will employ a multi-disciplinary approach to identify inhibitors of SARS-CoV-2 receptor binding and entry. Combining expertise in medicinal chemistry, computational chemical biology, structural biology, and virology, 3 parallel approaches will be employed: (1) Immediate testing of compound libraries (>1,400) using a high-throughput cell assay for SARS-CoV-2 receptor binding and entry. (2) Computational screening and design, synthesis, and evaluation (3). Development of protein-based inhibitors derived from the ACE2 receptor. The final evaluation of hits for effectiveness and drug resistance will be done with SARS-CoV-2.

Total amount: 343.200 €

CRUE - Universidades Españolas Consejo Superior de Investigaciones Científicas (CSIC) Banco Santander

Non-UV principal researchers

María-Jesús Pérez-Pérez (Instituto de Química Médica, IQM) and Ron Geller (Universitat de València)

Non-UV participating researchers

  • Jesús Rodríguez Díaz (Universitat de València)
  • Sonsoles Martin Santamaría (Centro de Investigaciones Biológicas Margarita Salas, CIB)
  • Alberto Marina Moreno, Vicente Rubio Zamora, Jerónimo Bravo Sicilia, José Luis Llacer Guerri (Instituto de Biomedicina de Valencia, IBV)

Start date
2020 April
End date
2021 December
Funding agencies:

CSIC-CRUE-Santander

Partners:

  • Instituto de Química Médica, IQM
  • Centro de Investigaciones Biológicas Margarita Salas, CIB
  • Instituto de Biomedicina de Valencia, IBV